TECH BIO-TECHNE Corp
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 842023 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.9%
TTM net income YoY120.5%
TTM EPS YoY124.5%
Revenue 3-yr CAGR2.4%
Net income 3-yr CAGR-11.3%
Margins
Gross margin65.8%
Operating margin19.6%
Net margin14.0%
FCF margin25.1%
EBITDA margin27.5%
Returns
ROE8.3%
ROA6.7%
ROIC (approx.)9.3%
Asset turnover0.48x
Leverage & solvency
Liabilities / assets17.9%
Debt / equity0.00x
Current ratio2.28x
Interest coverage27.16x
Cash quality & payout
Operating cash flow / net income1.96x
Accruals ratio-6.4%
Payout ratio29.1%
Capex / revenue2.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-09-30 | 2026Q4*2026-06-30 | 2026Q32026-03-31 | 2026Q22025-12-31 | 2026Q12025-09-30 | 2025Q4*2025-06-30 | 2025Q32025-03-31 | 2025Q22024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $299.71M | $321.19M | $311.42M | $295.88M | $286.56M | $316.96M | $316.18M | $297.03M |
| Cost of revenue | $103.09M | $109.80M | $103.13M | $104.60M | $98.44M | $118.15M | $101.62M | $103.14M |
| Gross profit | $196.62M | $211.39M | $208.29M | $191.28M | $188.11M | $198.81M | $214.56M | $193.89M |
| R&D expense | $26.34M | $23.95M | $23.45M | $23.12M | $24.24M | $26.03M | $24.58M | $25.02M |
| SG&A expense | $133.68M | $113.17M | $109.34M | $113.69M | $116.21M | $196.64M | $151.27M | $121.45M |
| Operating income | $36.60M | $74.28M | $75.50M | $54.46M | $47.66M | -$23.86M | $38.71M | $47.42M |
| Interest expense | $2.17M | $2.12M | $2.40M | $2.17M | $2.93M | $2.18M | $2.01M | $2.15M |
| Pretax income | $34.69M | $70.68M | $71.22M | $50.78M | $47.99M | -$22.86M | $38.27M | $42.88M |
| Income tax | $6.40M | $16.06M | $20.18M | $12.78M | $9.81M | -$5.18M | $15.69M | $7.99M |
| Net income | $28.29M | $54.62M | $51.05M | $38.01M | $38.19M | -$17.68M | $22.59M | $34.89M |
| EBITDA | $60.33M | $98.42M | $99.66M | $79.17M | $72.00M | $3.25M | $66.28M | $74.50M |
| EPS (basic) | 0.18 | — | 0.33 | 0.24 | 0.25 | — | 0.14 | 0.22 |
| EPS (diluted) | 0.18 | — | 0.32 | 0.24 | 0.24 | — | 0.14 | 0.22 |
| Dividends declared per share | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 |
| Weighted avg. shares (diluted) | 157.93M | — | 157.40M | 157.00M | 156.36M | — | 158.94M | 160.63M |
| Balance sheet | ||||||||
| Cash & equivalents | $350.04M | $264.71M | $209.82M | $172.88M | $144.96M | $162.19M | $140.67M | $177.55M |
| Short-term investments | — | — | — | — | — | — | $0 | $0 |
| Receivables | $203.06M | $216.59M | $214.56M | $184.61M | $183.90M | $206.88M | $237.14M | $217.94M |
| Inventory | $197.67M | $195.74M | $201.18M | $205.45M | $203.19M | $189.45M | $191.08M | $188.37M |
| Current assets | $824.83M | $744.40M | $688.05M | $637.43M | $609.51M | $608.30M | $627.24M | $634.64M |
| PP&E, net | $227.76M | $231.84M | $232.99M | $234.38M | $240.33M | $245.72M | $251.98M | $249.75M |
| Goodwill | $972.07M | $975.36M | $977.80M | $980.56M | $978.91M | $980.93M | $968.61M | $964.61M |
| Intangibles | $287.04M | $303.46M | $319.07M | $334.99M | $350.11M | $365.60M | $443.70M | $461.05M |
| Total assets | $2.64B | $2.59B | $2.55B | $2.52B | $2.53B | $2.56B | $2.64B | $2.67B |
| Current liabilities | $361.27M | $163.70M | $153.28M | $140.43M | $144.54M | $175.85M | $169.20M | $161.26M |
| Short-term debt | $200.00M | — | — | — | — | — | — | — |
| Long-term debt | — | $200.00M | $200.00M | $260.00M | $300.00M | $346.00M | $330.00M | $300.00M |
| Total debt | — | $200.00M | $200.00M | $260.00M | $300.00M | $346.00M | $330.00M | $300.00M |
| Total liabilities | $471.13M | $478.50M | $465.30M | $511.71M | $560.33M | $639.06M | $626.23M | $591.93M |
| Shareholders' equity | $2.17B | $2.11B | $2.09B | $2.01B | $1.97B | $1.92B | $2.02B | $2.08B |
| Net debt | — | -$64.71M | -$9.82M | $87.12M | $155.04M | $183.81M | $189.33M | $122.45M |
| Shares outstanding | 157.05M | 156.10M | 156.52M | 155.88M | 155.75M | 154.97M | 156.76M | 157.92M |
| Cash flow statement | ||||||||
| Operating cash flow | $73.11M | $95.42M | $86.66M | $82.41M | $27.59M | $98.20M | $41.12M | $84.35M |
| Capital expenditure | $5.92M | $8.48M | $9.09M | $5.92M | $5.36M | $4.89M | $10.12M | $6.82M |
| Free cash flow | $67.20M | $86.94M | $77.58M | $76.49M | $22.22M | $93.31M | $31.00M | $77.53M |
| Investing cash flow | -$3.93M | -$7.06M | -$5.82M | -$5.92M | $605,000 | $406,000 | -$8.87M | -$5.03M |
| Financing cash flow | $16.39M | -$33.21M | -$42.72M | -$48.99M | -$44.20M | -$90.45M | -$68.05M | -$83.84M |
| Depreciation & amortization | $23.73M | $24.14M | $24.17M | $24.71M | $24.34M | $27.11M | $27.57M | $27.08M |
| Stock-based compensation | $13.41M | $5.23M | $10.49M | $13.96M | $11.68M | $4.55M | $11.39M | $14.71M |
| Dividends paid | $12.56M | $12.48M | $12.52M | $12.47M | $12.44M | $12.39M | $12.58M | $12.74M |
| Share buybacks | — | $41.65M | $0 | $0 | $24,000 | $100.06M | $100.05M | — |
Free plan shows the latest 8 periods; Pro shows all 69 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.